- Home
- RAMP vs DVAX Comparison
RAMP vs DVAX Comparison
Compare RAMP & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- DVAX
- Stock Information
- Founded
- RAMP 2018
- DVAX 1996
- Country
- RAMP United States
- DVAX United States
- Employees
- RAMP N/A
- DVAX N/A
- Industry
- RAMP EDP Services
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- DVAX Health Care
- Exchange
- RAMP Nasdaq
- DVAX Nasdaq
- Market Cap
- RAMP 1.6B
- DVAX 1.5B
- IPO Year
- RAMP 1987
- DVAX 2004
- Fundamental
- Price
- RAMP $27.90
- DVAX $12.21
- Analyst Decision
- RAMP Buy
- DVAX Buy
- Analyst Count
- RAMP 7
- DVAX 2
- Target Price
- RAMP $41.14
- DVAX $22.00
- AVG Volume (30 Days)
- RAMP 514.5K
- DVAX 3.0M
- Earning Date
- RAMP 11-06-2024
- DVAX 11-07-2024
- Dividend Yield
- RAMP N/A
- DVAX N/A
- EPS Growth
- RAMP N/A
- DVAX N/A
- EPS
- RAMP 0.04
- DVAX 0.15
- Revenue
- RAMP $707,165,000.00
- DVAX $260,810,000.00
- Revenue This Year
- RAMP $12.97
- DVAX $23.13
- Revenue Next Year
- RAMP $8.72
- DVAX $19.60
- P/E Ratio
- RAMP $635.45
- DVAX $80.80
- Revenue Growth
- RAMP 13.84
- DVAX N/A
- 52 Week Low
- RAMP $21.45
- DVAX $9.74
- 52 Week High
- RAMP $42.66
- DVAX $15.01
- Technical
- Relative Strength Index (RSI)
- RAMP 62.83
- DVAX 52.22
- Support Level
- RAMP $24.72
- DVAX $11.61
- Resistance Level
- RAMP $29.20
- DVAX $13.74
- Average True Range (ATR)
- RAMP 0.79
- DVAX 0.52
- MACD
- RAMP 0.29
- DVAX 0.09
- Stochastic Oscillator
- RAMP 69.64
- DVAX 32.80
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.